Goldman Sachs’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$58.9M Buy
2,095,800
+855,800
+69% +$22.8M 0.01% 1445
2025
Q4
$30.9M Buy
1,240,000
+300,000
+32% +$7.57M ﹤0.01% 1948
2025
Q3
$24M Sell
940,000
-244,300
-21% -$6.03M ﹤0.01% 2093
2025
Q2
$28.7M Buy
1,184,300
+530,000
+81% +$12.4M ﹤0.01% 1797
2025
Q1
$16.6M Buy
654,300
+324,000
+98% +$8.48M ﹤0.01% 2204
2024
Q4
$8.76M Sell
330,300
-184,500
-36% -$5M ﹤0.01% 2924
2024
Q3
$14.9M Sell
514,800
-14,000
-3% -$408K ﹤0.01% 2324
2024
Q2
$14.8M Buy
528,800
+12,300
+2% +$339K ﹤0.01% 2136
2024
Q1
$14.3M Sell
516,500
-196,700
-28% -$5.46M ﹤0.01% 2137
2023
Q4
$20.5M Sell
713,200
-1,065,000
-60% -$32.2M ﹤0.01% 1858
2023
Q3
$59M Buy
1,778,200
+1,095,500
+160% +$38.7M 0.01% 1009
2023
Q2
$25M Sell
682,700
-18,000
-3% -$701K 0.01% 1659
2023
Q1
$28.6M Sell
700,700
-668,000
-49% -$28.9M 0.01% 1493
2022
Q4
$70.1M Sell
1,368,700
-112,600
-8% -$5.4M 0.02% 917
2022
Q3
$64.8M Sell
1,481,300
-70,800
-5% -$3.44M 0.02% 935
2022
Q2
$81.4M Sell
1,552,100
-143,200
-8% -$7.3M 0.02% 816
2022
Q1
$87.8M Sell
1,695,300
-64,700
-4% -$3.36M 0.02% 846
2021
Q4
$104M Buy
1,760,000
+403,300
+30% +$20M 0.02% 789
2021
Q3
$58.4M Buy
1,356,700
+286,200
+27% +$12.7M 0.01% 1173
2021
Q2
$41.9M Buy
1,070,500
+515,000
+93% +$20M 0.01% 1413
2021
Q1
$20.1M Buy
555,500
+394,500
+245% +$14M 0.01% 1926
2020
Q4
$5.93M Buy
161,000
+81,950
+104% +$3.01M ﹤0.01% 2892
2020
Q3
$2.75M Buy
+79,050
New +$2.77M ﹤0.01% 3343
2020
Q1
Sell
-85,269
Closed -$3.17M 5472
2019
Q4
$3.17M Sell
85,269
-105,400
-55% -$3.75M ﹤0.01% 3310
2019
Q3
$6.5M Sell
190,669
-716,087
-79% -$26M ﹤0.01% 2662
2019
Q2
$37.3M Sell
906,756
-1,572,990
-63% -$62.5M 0.01% 1364
2019
Q1
$99.9M Buy
2,479,746
+1,405,509
+131% +$56.3M 0.03% 666
2018
Q4
$44.5M Buy
1,074,237
+290,904
+37% +$12.1M 0.01% 1177
2018
Q3
$32.8M Sell
783,333
-223,869
-22% -$8.62M 0.01% 1539
2018
Q2
$34.7M Sell
1,007,202
-503,285
-33% -$17.2M 0.01% 1494
2018
Q1
$50.9M Sell
1,510,487
-661,280
-30% -$22.7M 0.01% 1187
2017
Q4
$74.6M Buy
2,171,767
+131,012
+6% +$4.47M 0.02% 987
2017
Q3
$69.1M Buy
2,040,755
+61,343
+3% +$1.97M 0.02% 1058
2017
Q2
$63.1M Buy
1,979,412
+421,073
+27% +$13.3M 0.02% 1088
2017
Q1
$50.6M Sell
1,558,339
-12,882,620
-89% -$406M 0.01% 1213
2016
Q4
$445M Sell
14,440,959
-672,558
-4% -$20.5M 0.13% 143
2016
Q3
$486M Buy
15,113,517
+428,557
+3% +$14.3M 0.15% 104
2016
Q2
$491M Sell
14,684,960
-7,357,026
-33% -$235M 0.16% 96
2016
Q1
$620M Sell
22,041,986
-1,727,190
-7% -$49.3M 0.2% 74
2015
Q4
$728M Buy
23,769,176
+15,047,326
+173% +$473M 0.23% 67
2015
Q3
$260M Buy
8,721,850
+5,338,088
+158% +$171M 0.09% 223
2015
Q2
$108M Sell
3,383,762
-11,339,142
-77% -$370M 0.03% 615
2015
Q1
$486M Buy
14,722,904
+12,824,650
+676% +$408M 0.16% 122
2014
Q4
$56.1M Sell
1,898,254
-294,804
-13% -$8.45M 0.02% 1018
2014
Q3
$61.5M Sell
2,193,058
-907,494
-29% -$25.5M 0.02% 924
2014
Q2
$87.3M Buy
3,100,552
+384,394
+14% +$11M 0.03% 740
2014
Q1
$82.8M Sell
2,716,158
-431,402
-14% -$12.9M 0.03% 706
2013
Q4
$91.5M Buy
3,147,560
+172,961
+6% +$5.03M 0.03% 671
2013
Q3
$81.1M Sell
2,974,599
-2,075,220
-41% -$56.5M 0.03% 684
2013
Q2
$134M Buy
+5,049,819
New +$140M 0.05% 420

Other funds holding PFE

Goldman Sachs's PFE Position: Q1 2026 in Review

Goldman Sachs increased its Pfizer (PFE) stake by 18% in Q1 2026, buying an estimated $188M and bringing the position to 47,105,556 shares worth $1.32B. The position accounts for 0.15% of the portfolio, ranked #113.

Goldman Sachs first reported a position in PFE in Q2 2013 and has held it in 52 quarters since. The position peaked at $3.14B in Q1 2016. 2,937 funds tracked by Wall St. Rank hold PFE as of Q1 2026.

  • Goldman Sachs held 47,105,556 shares of Pfizer worth $1.32B as of Q1 2026.
  • Goldman Sachs bought 7,049,994 Pfizer shares in Q1 2026, an estimated $188M.
  • Pfizer made up 0.15% of Goldman Sachs's portfolio in Q1 2026, its #113 holding.
  • Goldman Sachs first reported a position in Pfizer in Q2 2013 and has held it in 52 quarters since.
  • Goldman Sachs's Pfizer position peaked at $3.14B in Q1 2016.
  • 2,937 funds tracked by Wall St. Rank held Pfizer as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.